echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > ALK-1 monoclonal antibody/Opdivo combination for first-line treatment of advanced liver cancer is clinically approved in China

    ALK-1 monoclonal antibody/Opdivo combination for first-line treatment of advanced liver cancer is clinically approved in China

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pioneer Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China has recently approved its ALK-1 monoclonal antibody (GT90001C), and Bristol-Myers Squibb's (BMS) anti-PD-1 monoclonal antibody nivolumab (English trade name Opdivo) Combined clinical trial for the treatment of patients with advanced hepatocellular carcinoma (HCC) who have not been systemically treated


    Liver cancer is the fourth most common cancer in China and the second most fatal cancer.


    The Phase 2 clinical trial of ALK-1 monoclonal antibody/nivolumab combination therapy for the second-line treatment of patients with advanced hepatocellular carcinoma was first launched in 2019


    Reference materials:

    [1] Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma.


    [2] The clinical trial of the first-line treatment of advanced hepatocellular carcinoma with the combination of ALK-1 monoclonal antibody and O drug by Kaixing Pharmaceutical was approved by the China Food and Drug Administration.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.